Several other analysts have also commented on CTLT. Bank of America Corp. raised shares of Catalent from a neutral rating to a buy rating and set a $28.00 price target for the company in a research report on Monday, June 20th. They noted that the move was a valuation call. Wells Fargo & Co. raised shares of Catalent from a market perform rating to an outperform rating in a research report on Tuesday, June 21st. Zacks Investment Research raised shares of Catalent from a strong sell rating to a hold rating in a research report on Tuesday, July 5th. Jefferies Group reaffirmed a hold rating on shares of Catalent in a research report on Thursday, August 4th. Finally, TheStreet raised shares of Catalent from a sell rating to a hold rating in a research report on Wednesday, August 17th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. The company has an average rating of Hold and a consensus target price of $28.67.
Shares of Catalent (NASDAQ:CTLT) traded down 0.42% during mid-day trading on Tuesday, reaching $23.90. 10,479 shares of the company traded hands. The firm has a market capitalization of $2.98 billion and a price-to-earnings ratio of 26.85. Catalent has a 52 week low of $18.92 and a 52 week high of $32.24. The firm has a 50-day moving average price of $25.20 and a 200 day moving average price of $25.55.
Catalent (NASDAQ:CTLT) last released its quarterly earnings results on Monday, August 29th. The company reported $0.52 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.53 by $0.01. The business had revenue of $532.20 million for the quarter. The company’s revenue was up 4.3% on a year-over-year basis. During the same quarter last year, the business earned $0.61 earnings per share. On average, analysts anticipate that Catalent will post $1.40 earnings per share for the current year.
In other Catalent news, major shareholder Blackstone Management Associat sold 17,100,705 shares of the firm’s stock in a transaction that occurred on Friday, September 9th. The shares were sold at an average price of $23.58, for a total transaction of $403,234,623.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Large investors have recently modified their holdings of the company. FMR LLC boosted its stake in shares of Catalent by 89.1% in the second quarter. FMR LLC now owns 14,597,087 shares of the company’s stock worth $335,587,000 after buying an additional 6,877,549 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Catalent by 15.2% in the second quarter. Vanguard Group Inc. now owns 7,881,737 shares of the company’s stock worth $181,201,000 after buying an additional 1,039,117 shares during the last quarter. BlackRock Fund Advisors boosted its stake in shares of Catalent by 15.5% in the second quarter. BlackRock Fund Advisors now owns 5,721,096 shares of the company’s stock worth $131,528,000 after buying an additional 767,019 shares during the last quarter. Janus Capital Management LLC boosted its stake in shares of Catalent by 1.5% in the second quarter. Janus Capital Management LLC now owns 5,061,371 shares of the company’s stock worth $116,361,000 after buying an additional 73,233 shares during the last quarter. Finally, UBS Asset Management Americas Inc. boosted its stake in shares of Catalent by 23.2% in the second quarter. UBS Asset Management Americas Inc. now owns 4,252,650 shares of the company’s stock worth $97,768,000 after buying an additional 799,498 shares during the last quarter.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with MarketBeat.com's FREE daily email newsletter.